News

23. April 2018

Probiodrug AG

Probiodrug Appoints Dr. Ulrich Dauer as Chief Executive Officer

  • Dr. Ulrich Dauer to team up with Chief Development Officer, Dr. Inge Lues, effective May 1, 2018; Dr. Konrad Glund and Dr. Hendrik Liebers to continue in advisory roles
10. April 2018

NOXXON Pharma N.V.

NOXXON ANNOUNCES INITIATION OF ANALYST COVERAGE BY AURGALYS

10. April 2018

Probiodrug AG

Probiodrug to attend and present at International Conferences in April 2018

3. April 2018

Probiodrug AG

Probiodrug reports full year 2017 financial results

  • PQ912 delivers positive pharmacodynamic and efficacy results in a Phase 2a study in early stage AD patients - data presented at CTAD, Boston, November 2017
  • PQ912 Phase 2b core program...
27. März 2018

Probiodrug AG

Probiodrug AG to Publish its Full Year 2017 Results on 3 April 2018

22. März 2018

NOXXON Pharma N.V.

NOXXON ANNOUNCES CONVOCATION OF AN EXTRA-ORDINARY
GENERAL MEETING OF SHAREHOLDERS

16. März 2018

Probiodrug AG

Probiodrug to present at 255th ACS National Meeting & Exposition

The Inhibition of Glutaminyl Cyclase as a New Concept for the Treatment of Alzheimer's Disease: PQ912, the First-In-Class QC-Inhibitor in Clinical Development for AD

13. März 2018

NOXXON Pharma N.V.

NOXXON VERHANDELT ODIRNANE BSA-FINANZIERUNGSVEREINBARUNG ZUR AUFHEBUNG DER EINSEITIGEN OPTION DES INVESTORS FÜR DIE ZEICHNUNG VON TRANCHEN UND KÜNDIGUNG EXISTIERENDER BSAAKTIENOPTIONSSCHEINE

27. Februar 2018

Probiodrug AG

Probiodrug to attend and present at international conferences in March 2018

31. Januar 2018

NOXXON Pharma N.V.

HALF-YEARLY REPORT ON THE LIQUIDITY CONTRACT WITH INVEST SECURITIES

Seiten